Inactive

The Defense Health Agency (DHA) Southeast Contracting Division intends to negotiate a contract on a sole source basis (IAW FAR 13.501(a) sole source acquisitions). The proposed source is Hologic Sales... The Defense Health Agency (DHA) Southeast Contracting Division intends to negotiate a contract on a sole source basis (IAW FAR 13.501(a) sole source acquisitions). The proposed source is Hologic Sales and Service, LLC (Hologic) of 250 Campus Drive, Marlborough, MA 01752. The requirement is Brand Name Only (BNO) to the Hologic Panther. The requirement is for the following procedures: Hologic Aptima SARS-CoV-2 Assay, 250-test (PRD-06419), Hologic 123Aptima SARS-CoV-2 Assay Controls (PRD-06420), which are required for COVID-19 real-time testing on the existing Hologic Panther analyzer; Hologic M GEN Aptima, 100-T, AS, (PRD-03919), is required for testing for Mycoplasma genitalium testing on the Hologic Panther analyzer; Hologic BV Assay, Aptima, 100T, IVD (PRD-05186), is required for testing for Bacterial Vaginosis on the Hologic Panther analyzer; and Hologic CV/TV Assay, Aptima, 100T, IVD (PRD-05189), is required for testing for Candida vaginitis and trichomoniasis on the Hologic Panther analyzer. The following quantities are required: Item Number Product Quantity PRD-06419 Aptima SARS-CoV-2 Assay EUA, 250-test 123 PRD-06420 Aptima SARS-CoV-2 Assay Controls 62 PRD-03919 M GEN Aptima, 100-T, AS 57 PRD-05186 BV Assay, Aptima, 100T, IVD 55 PRD-05189 CV/TV Assay, Aptima, 100T 55 Anticipated delivery dates starting in November. Four (4) option periods are anticipated. There are not set-aside restrictions for this requirement. The intended procurement will be classified under North America Industry Classification System (NAICS) 325413-In-Vitro Diagnostic Substance Manufacturing. This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same product. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. If a vendor challenges the basis of this requirement, please email product capability statements (formats for submission: PDF, MS Word, or MS Excel) to Derek Bell at derek.j.bell.civ@health.mil. Closing date for challenges is no later than 10:00 AM ET on 11 October 2023. No phone calls will be accepted.